How does Molnupiravir acts against viral replication in COVID-19 ?
• Molnupiravir in Covid1...
Members of the National Task Force for COVID-19 were not in favour of including the drug in the national treatment guidelines citing that it does not have much benefit in the treatment of coronavirus infection and that there were safety concerns,” an official source said.
Indian Council of Medical Research chief Balram Bhargava had said Molnupiravir had major safety concerns. He added that the World Health Organization and the U.K. had not included it for treatment. He said this drug could cause defects in a developing foetus and could damage the muscles also.
“Contraception will have to be done for three months for male and female if this drug is given because the child born could be problematic due to teratogenic influence,” he said.
Molnupiravir is not authorized for use in patients younger than 18 years of age because molnupiravir may affect bone and cartilage growth.
It is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in patients hospitalized due to COVID-19 because benefit of treatment has not been observed in people when treatment started after hospitalization due to COVID-19.
Molnupiravir is not a substitute for vaccination in individuals for whom COVID-19 vaccination and a booster dose are recommended.
The FDA has approved one vaccine and authorized others to prevent COVID-19 and serious clinical outcomes associated with a COVID-19 infection, including hospitalization and death.
Based on findings from animal reproduction studies, molnupiravir may cause fetal harm when administered to pregnant individuals.
Therefore, molnupiravir is not recommended for use during pregnancy.
Molnupiravir is only authorized to be prescribed to a pregnant individual after the prescribing healthcare provider has determined that the benefits of being treated with molnupiravir would outweigh the risks for that individual patient and after the prescribing health care provider has communicated the known and potential benefits and the potential risks of using molnupiravir during pregnancy to the pregnant individual.
Females of childbearing potential are advised to use a reliable method of birth control correctly and consistently during treatment with molnupiravir and for four days after the final dose.
Males of reproductive potential who are sexually active with females of childbearing potential are advised to use a reliable method of birth control correctly and consistently during treatment with molnupiravir and for at least three months after the final dose.
Questions and concerns about reliable birth control methods that are appropriate for use during treatment with molnupiravir, as well as how molnupiravir may affect sperm cells, should be directed at one’s healthcare provider.
#drvinoth #covid19 #medi360 #molnupiravir #icmr #icmr2022 #fdaapproved #sideeffects #teratogenicity #birthdefects #cartilage #ligament #muscleinjury #contraception #covidtreatmentathome #covidtreatment #education #knowledge